MXPA04006275A - Composiciones farmaceuticas que comprenden un inhibidor de fosfodiesterasa multifuncional y un inhibidor de captacion de adenosina. - Google Patents
Composiciones farmaceuticas que comprenden un inhibidor de fosfodiesterasa multifuncional y un inhibidor de captacion de adenosina.Info
- Publication number
- MXPA04006275A MXPA04006275A MXPA04006275A MXPA04006275A MXPA04006275A MX PA04006275 A MXPA04006275 A MX PA04006275A MX PA04006275 A MXPA04006275 A MX PA04006275A MX PA04006275 A MXPA04006275 A MX PA04006275A MX PA04006275 A MXPA04006275 A MX PA04006275A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- pharmaceutical compositions
- adenosine uptake
- multifunctional
- multifunctional phosphodiesterase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion se relaciona a composiciones farmaceuticas las cuales comprenden por lo menos un inhibidor de fosfodiesterasa multifuncional (MPDEI) y por lo menos un inhibidor de captacion de adenosina. La presente invencion tambien se relaciona a composiciones que comprenden cilostazol y dipiridamol y su uso.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34236701P | 2001-12-27 | 2001-12-27 | |
US41254602P | 2002-09-23 | 2002-09-23 | |
PCT/US2002/041531 WO2003057222A1 (en) | 2001-12-27 | 2002-12-26 | Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA04006275A true MXPA04006275A (es) | 2004-10-04 |
Family
ID=26992976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04006275A MXPA04006275A (es) | 2001-12-27 | 2002-12-26 | Composiciones farmaceuticas que comprenden un inhibidor de fosfodiesterasa multifuncional y un inhibidor de captacion de adenosina. |
Country Status (15)
Country | Link |
---|---|
US (3) | US20050165030A1 (es) |
EP (1) | EP1461039B1 (es) |
JP (1) | JP2005517680A (es) |
KR (1) | KR20040083072A (es) |
CN (1) | CN1607952A (es) |
AR (1) | AR038091A1 (es) |
AU (1) | AU2002360798A1 (es) |
BR (1) | BR0215392A (es) |
CA (1) | CA2471846A1 (es) |
DK (1) | DK1461039T3 (es) |
ES (1) | ES2525418T3 (es) |
MX (1) | MXPA04006275A (es) |
PT (1) | PT1461039E (es) |
TW (1) | TW200301135A (es) |
WO (1) | WO2003057222A1 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8506934B2 (en) | 2005-04-29 | 2013-08-13 | Robert I. Henkin | Methods for detection of biological substances |
US20090297596A1 (en) * | 2005-05-23 | 2009-12-03 | Elan Pharma International Limited | Nanoparticulate and Controlled Release Compositions Comprising a Platelet Aggregation Inhibitor |
US7811549B2 (en) * | 2006-07-05 | 2010-10-12 | Adenobio N.V. | Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects |
US20090042849A1 (en) * | 2006-12-06 | 2009-02-12 | Yochai Birnbaum | Phosphorylation of 5-lipoxygenase at ser523 and uses thereof |
WO2008076841A1 (en) * | 2006-12-14 | 2008-06-26 | Biokey, Inc. | Pharmaceutical composition for reducing the risks associated with cardiovascular and cerebrovascular diseases |
US8293489B2 (en) | 2007-01-31 | 2012-10-23 | Henkin Robert I | Methods for detection of biological substances |
PL2157973T3 (pl) * | 2007-05-22 | 2015-12-31 | Otsuka Pharma Co Ltd | Lek zawierający pochodną karbostyrylu i donepezil do leczenia choroby Alzheimera |
US20090185973A1 (en) * | 2008-01-22 | 2009-07-23 | Adenobio N.V. | Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects |
WO2009100534A1 (en) * | 2008-02-14 | 2009-08-20 | Kardiatech, Inc. | Combination therapy to treat vascular disorders |
US20100069326A1 (en) * | 2008-02-14 | 2010-03-18 | Wasimul Haque | Combination Therapies to Treat Cardio- and Cerebro-Vascular Disorders |
US8580801B2 (en) * | 2008-07-23 | 2013-11-12 | Robert I. Henkin | Phosphodiesterase inhibitor treatment |
KR101763656B1 (ko) | 2009-06-29 | 2017-08-01 | 인사이트 홀딩스 코포레이션 | Pi3k 저해물질로서의 피리미디논 |
US20110092456A1 (en) * | 2009-10-19 | 2011-04-21 | Yochai Birnbaum | Methods of increasing cAMP levels and uses thereof |
TW201130842A (en) * | 2009-12-18 | 2011-09-16 | Incyte Corp | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors |
WO2011075643A1 (en) * | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
JP5816678B2 (ja) | 2010-04-14 | 2015-11-18 | インサイト・コーポレイションIncyte Corporation | PI3Kδ阻害剤としての縮合誘導体 |
WO2011163195A1 (en) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Fused pyrrole derivatives as pi3k inhibitors |
JP5961187B2 (ja) | 2010-12-20 | 2016-08-02 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Pi3k阻害剤としてのn−(1−(置換フェニル)エチル)−9h−プリン−6−アミン |
WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
WO2013033569A1 (en) | 2011-09-02 | 2013-03-07 | Incyte Corporation | Heterocyclylamines as pi3k inhibitors |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
WO2015126944A1 (en) | 2014-02-18 | 2015-08-27 | Henkin Robert I | Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell |
WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
NZ734993A (en) | 2015-02-27 | 2024-03-22 | Incyte Holdings Corp | Salts of pi3k inhibitor and processes for their preparation |
US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
JP7036670B2 (ja) * | 2018-05-31 | 2022-03-15 | アークレイ株式会社 | 血液中の稀少細胞検査、該検査ための血液処理方法及び採血管 |
JP7332489B2 (ja) * | 2019-01-28 | 2023-08-23 | サントリーホールディングス株式会社 | ホスホジエステラーゼ3阻害用組成物及び血小板凝集抑制用組成物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3627423A1 (de) * | 1986-08-13 | 1988-02-18 | Thomae Gmbh Dr K | Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung |
US5270047A (en) * | 1991-11-21 | 1993-12-14 | Kauffman Raymond F | Local delivery of dipyridamole for the treatment of proliferative diseases |
US6331543B1 (en) * | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
US6037346A (en) * | 1997-10-28 | 2000-03-14 | Vivus, Inc. | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
US6761903B2 (en) * | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
WO2002058734A2 (en) * | 2001-01-26 | 2002-08-01 | Schering Corporation | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions |
-
2002
- 2002-12-25 TW TW091137339A patent/TW200301135A/zh unknown
- 2002-12-26 AU AU2002360798A patent/AU2002360798A1/en not_active Abandoned
- 2002-12-26 US US10/499,965 patent/US20050165030A1/en not_active Abandoned
- 2002-12-26 ES ES02796079.8T patent/ES2525418T3/es not_active Expired - Lifetime
- 2002-12-26 KR KR10-2004-7010086A patent/KR20040083072A/ko not_active Application Discontinuation
- 2002-12-26 DK DK02796079.8T patent/DK1461039T3/en active
- 2002-12-26 WO PCT/US2002/041531 patent/WO2003057222A1/en active Application Filing
- 2002-12-26 JP JP2003557580A patent/JP2005517680A/ja not_active Withdrawn
- 2002-12-26 MX MXPA04006275A patent/MXPA04006275A/es unknown
- 2002-12-26 CA CA002471846A patent/CA2471846A1/en not_active Abandoned
- 2002-12-26 EP EP02796079.8A patent/EP1461039B1/en not_active Expired - Lifetime
- 2002-12-26 CN CNA02826147XA patent/CN1607952A/zh active Pending
- 2002-12-26 PT PT2796079T patent/PT1461039E/pt unknown
- 2002-12-26 BR BR0215392-0A patent/BR0215392A/pt not_active Application Discontinuation
- 2002-12-27 AR ARP020105132A patent/AR038091A1/es unknown
-
2007
- 2007-10-27 US US11/925,922 patent/US20080200484A1/en not_active Abandoned
-
2010
- 2010-01-08 US US12/684,786 patent/US20100184784A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR0215392A (pt) | 2004-12-07 |
EP1461039B1 (en) | 2014-10-22 |
PT1461039E (pt) | 2014-12-12 |
KR20040083072A (ko) | 2004-09-30 |
CA2471846A1 (en) | 2003-07-17 |
AR038091A1 (es) | 2004-12-29 |
ES2525418T3 (es) | 2014-12-22 |
JP2005517680A (ja) | 2005-06-16 |
WO2003057222A1 (en) | 2003-07-17 |
US20100184784A1 (en) | 2010-07-22 |
EP1461039A1 (en) | 2004-09-29 |
US20050165030A1 (en) | 2005-07-28 |
AU2002360798A1 (en) | 2003-07-24 |
CN1607952A (zh) | 2005-04-20 |
TW200301135A (en) | 2003-07-01 |
US20080200484A1 (en) | 2008-08-21 |
DK1461039T3 (en) | 2015-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA04006275A (es) | Composiciones farmaceuticas que comprenden un inhibidor de fosfodiesterasa multifuncional y un inhibidor de captacion de adenosina. | |
MXPA03009647A (es) | Heterociclildicarbamidas como inhibidores de caspasa. | |
IL157109A0 (en) | Quinazolines as mmp-13 inhibitors | |
MY135721A (en) | Amidino compounds useful as nitric oxide synthase inhibitors | |
HK1072200A1 (en) | Pro-micelle pharmaceutical compositions | |
EP1407785A4 (en) | MEDICAL COMPOSITIONS | |
HK1065944A1 (en) | Medicinal compositions | |
PL368370A1 (en) | Glyphosate composition | |
PL369404A1 (en) | Impact-resistant polyolefin compositions | |
GB0105065D0 (en) | Lubricant compositions | |
IL205407A0 (en) | Hyaluronic acid antagonist and inhibitor compositions and uses thereof | |
ZA200302929B (en) | Compositions comprising cyclohexamantane. | |
EP1545509A4 (en) | CASPASE HEMMER AS CANCER | |
EP1425262A4 (en) | ACYLTHIOL AND THIOL COMPOSITIONS AS ANTI-HIV AGENTS AND ANTI-RETROVIRAL AGENTS | |
IL159863A0 (en) | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents | |
HUP0400438A3 (en) | Broadspectrum 2-amino-benzoxazole-6-sulfonamides, their use as hiv protease inhibitor and pharmaceutical compositions containing them | |
GB0200763D0 (en) | Compositions | |
HUP0303420A3 (en) | Synergetic fungicidal compositions based on pyridylmethylbenzamide and propamocarb derivative and use thereof | |
AU2002365093A8 (en) | Therapeutic compositions | |
TW200501957A (en) | Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin Ⅱ antagonist for stroke prevention | |
GB0130490D0 (en) | Lubricant compositions | |
GB0104752D0 (en) | Pharmaceutical compositions | |
IL160960A0 (en) | Reduced toxicity cisplatin formulations and methods for using the same | |
GB0109428D0 (en) | Therapeutic compositions | |
WO2002078641A3 (en) | Pyrrolidine sulfonamides |